| 13.17 1.22 (10.21%) | 06-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 17.34 | 1-year : | 20.25 |
| Resists | First : | 14.85 | Second : | 17.34 |
| Pivot price | 12.43  |
|||
| Supports | First : | 8.99 | Second : | 5.37 |
| MAs | MA(5) : | 12.16 |
MA(20) : | 12.4 |
| MA(100) : | 7.02 |
MA(250) : | 4.34 |
|
| MACD | MACD : | 1 |
Signal : | 1.2 |
| %K %D | K(14,3) : | 36.8 |
D(3) : | 28.2 |
| RSI | RSI(14): 61 |
|||
| 52-week | High : | 14.85 | Low : | 1.34 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ QTTB ] has closed below upper band by 17.2%. Bollinger Bands are 29.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 13.18 - 13.23 | 13.23 - 13.29 |
| Low: | 11.87 - 11.92 | 11.92 - 11.98 |
| Close: | 13.07 - 13.16 | 13.16 - 13.26 |
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.
Fri, 26 Jun 2026
Q32 Bio Inc Actuals & Estimates (NASDAQ:QTTB) - TradingView
Thu, 25 Jun 2026
Q32 Bio (NASDAQ: QTTB) files $300M shelf; May 26 $55M placement noted - Stock Titan
Thu, 25 Jun 2026
Price to sales forward of Q32 Bio Inc. – NASDAQ:QTTB - TradingView
Tue, 16 Jun 2026
Director Mary Thistle receives 9,810 Q32 Bio (QTTB) stock options at $12.64 - Stock Titan
Tue, 16 Jun 2026
Director Isaac Manke receives 9,810 Q32 Bio (QTTB) stock options at $12.64 strike - Stock Titan
Tue, 02 Jun 2026
Q32 Bio Inc. Stock (QTTB) Opinions on Massive Price Surge - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 17 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 3.9 (%) |
| Held by Institutions | 107.9 (%) |
| Shares Short | 862 (K) |
| Shares Short P.Month | 653 (K) |
| EPS | 2.77 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.17 |
| Profit Margin | 61.8 % |
| Operating Margin | 39.8 % |
| Return on Assets (ttm) | 18.7 % |
| Return on Equity (ttm) | 157.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 2.26 |
| Sales Per Share | 3.16 |
| EBITDA (p.s.) | 1.28 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -27 (M) |
| Levered Free Cash Flow | 10 (M) |
| PE Ratio | 4.73 |
| PEG Ratio | 0 |
| Price to Book value | 4.15 |
| Price to Sales | 4.15 |
| Price to Cash Flow | -8.16 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|